Broydrick Blog

Genetically Modified Pigs Could Ease Organ Shortage

Genetically Modified Pigs Could Ease Organ Shortage

My friend and client Dr. Joe Tector is doing extraordinary work on solving the problem of the shortage of organs for transplantation. Through his research as shown in this Wall Street Journal article it may be possible to develop pig organs that can be transplanted into humans. Today, thousands die because of organ shortages and…

Read More Read More

Update on Cologuard and TRICARE

Update on Cologuard and TRICARE

As of the most recent update to TRICARE’s preventive services policies, Exact Science’s Cologuard – the most effective, non-invasive colorectal cancer screening exam – is now given first-dollar coverage for 9.4 million active-duty, reserve, and National Guard personnel, veterans, and their dependents. The revision brings TRICARE into compliance with the most recent United States Preventive…

Read More Read More

Cologuard Included in NCQA’s HEDIS

Cologuard Included in NCQA’s HEDIS

As of three days ago Exact Sciences’ Cologuard – the most effective, non-invasive colorectal cancer screening exam – is now included in the National Committee for Quality Assurance’s (NCQA) Healthcare Effectiveness Data and Information Set (HEDIS). Inclusion in HEDIS means that physicians will receive quality credit for providing patients an exam given an “A” rating…

Read More Read More

Direct Supply awarded $22.5 million in tax credits

Direct Supply awarded $22.5 million in tax credits

We are very happy and proud to have assisted Direct Supply in their successful application to the Wisconsin Economic Development Corporation for up to $22.5 million in tax credits for their planned expansion. Direct Supply is the leading supply chain expert in the long term care market based an a very successful employee ownership model.…

Read More Read More

A Great Day in the Fight Against Cancer!

A Great Day in the Fight Against Cancer!

In August 2014, Exact Sciences’ Cologuard became the first medical product ever to receive simultaneous FDA and CMS approval. However, in November 2015, the USPSTF released a draft of its colorectal cancer screening recommendations listing Cologuard as an “Alternative Test” — a designation that would have had profound consequences for all coverage decisions tied to…

Read More Read More